
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is a pharmaceutical company focused on developing treatments for neurodegenerative diseases, including its current leading product, ZUNVEYL. Financial and commercial metrics have shown strong growth and continued market uptake, indicating a positive outlook for the company. Upcoming pipeline initiatives and post-approval studies are expected to provide substantial support for further commercial expansion. Risks include slower market uptake and setbacks in clinical testing. A new board director with extensive experience in the biopharmaceutical industry has been added to the company's leadership team. Based on a discounted cash flow valuation methodology, Alpha Cognition's prospects suggest a total enterprise value of $580M, with a 12-month price objective of $20 per share.
Bears say
Alpha Cognition is performing better than expected in terms of revenue and net loss, with an estimated full-year 2026 revenue of $26 million and a net loss of $1.28 per share. However, the negative impact of changes in the fair value of warrants and moderately higher operating expenses led to a net loss of $0.40 per share in the second quarter. Additionally, there are risks to consider, including potential issues with market uptake of their lead product, ZUNVEYL, and setbacks in clinical testing. The recent settlement agreement eliminates certain future payment obligations, but could also potentially limit the company's future revenue potential. Based on a discounted cash flow valuation, the current price target for Alpha Cognition is $18 per share, representing potential downside risk compared to the current trading price.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares